Brief: Contrafect Announces Up To $18.9 Million In Funding From Carb-X
20/07/2020 12:48
July 20 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES UP TO $18.9 MILLION IN FUNDING FROM
CARB-X
TO SUPPORT ACCELERATION OF THE CF-370 PROGRAM FOR TREATING
PSEUDOMONAS AERUGINOSA INFECTIONS TOWARDS CLINICAL STAGE
DEVELOPMENT
* CONTRAFECT CORP - AWARD PROVIDES INITIAL FUNDING OF $4.9
MILLION
* CONTRAFECT CORP - COULD RECEIVE ADDITIONAL FUNDING IF
CERTAIN
PROJECT MILESTONES ARE MET
Source text for Eikon: ID:nGNX2l1hn6
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370